Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate

Freeline Therapeutics Holdings plc  (NASDAQ: FRLN ) announced the presentation of safety and initial efficacy data  from the first cohort of the Phase 1/2 B-LIEVE trial for FLT180a for hemophilia B. As of the data cut-off of May 23, 2022, a one-time FLT180a dose of 7.7e11 vg/kg generated a rapid increase of coagulation factor ... Full story available on